M.V. Solodun - Post-graduate Student, Ryazan State Medical University Е-mail: mariyasolodun@mail.ru S.S. Yakushin - Dr.Sc. (Med.), Professor, Ryazan State Medical University Е-mail: ssyakushin@yandex.ru

To analyze the prognostic value of gene polymorphisms ACE (D/I), SLCO1B1 (Val174Ala), LIPC (C514T), CYP2C19*2, CYP2C19*3, ADRB1 (Ser49Gly), ADRB1 (Arg389Gly) of patients with ST-segment elevation myocardial infarction (STEMI). 155 patients with STEMI were involved into the study. All patients were prescribed all recommended preparations improving prognosis from the first day of hospitalization. Prognosis was assessed by a combined endpoint, including cardiovascular mortality, nonfatal myocardial infarction, unplanned revascularization of coronary arteries and hospitalization for unstable angina, throughout 12 months. The II genotype of the polymorphic gene ACE (I/D) is an independent predictor of the 12-month STEMI favorable outcome. Allele Ser of the polymorphic gene ADRB1 Ser49Gly is associated with an increased incidence of adverse cardiovascular events within 12 months after STEMI.

 

1. Bellil S., JAkushin S.S., Aksentev S.B., JUnevich D.S. Sravnitelnyjj prognoz u bolnykh pozhilogo i starcheskogo vozrasta s perenesennym infarktom miokarda s podemom segmenta ST v techenie 12 mesjacev nabljudenija v zavisimosti ot razlichnykh skhem reperfuzionnojj terapii // Rossijjskijj mediko-biologicheskijj vestnik im. akademika I.P. Pavlova. 2015. № 1. S. 90-94.
2. Fox K.A., Dabbous O.H., Goldberg R.J. et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE) // BMJ. 2006.   V. 333. P. 1091.
3. Bojjcov S.A., JAkushin S.S., Liferov R.A. i dr. Uglublennyjj analiz rasprostranennosti ostrykh form IBS i smertnosti ot nikh v Rjazani (v ramkakh mnogocentrovogo issledovanija REZONANS) // Kardiologicheskijj vestnik. 2008. T. 3. № 2 (XV). S. 31-38.
4. Solodun M.V., Aksentev S.B., Nikiforov A.A. Pervye rezultaty ocenki prognosticheskojj znachimosti polimorfizma gena CYP2C19 u pacientov, perenesshikh infarkt miokarda // Nauka molodykh (Eruditio Juvenium). 2013.   № 3. S. 43-47.
5. Solodun M.V. Farmakoterapija pri infarkte miokarda: vklad geneticheskikh faktorov // Rossijjskijj kardiologicheskijj zhurnal. 2016. № 3 (131). S. 111-116.
6. Magnusson Y., Levin M.C., Eggertsen R. Ser49Gly of beta1-adrenergic receptor is associated with effective betablocker dose in dilated cardio­myopathy // Clin. Pharmacol. Ther. 2005.   V. 78. № 3. P. 221-231.
7. Borjesson M., Magnusson Y., Hjalmarson A. et al. A novel polymorphism in the gene coding for the beta1-adrenergic receptor associated with survival in patients with heart failure // Eur. Heart J. 2000. V. 21. P. 1853-1858.
8. Araujo M.A., Goulart L.R., Cordeiro E.R. et al. Genotypic interactions of renin-angiotensin system genes in myocardial infarction // Int. J. Cardiol. 2005. V. 103. № 1. P. 27-32.
9. Boeva O.I., SHHeglova E.V. Vozmozhnosti prognozirovanija neblagoprijatnogo iskhoda u bolnykh, perenjosshikh ostryjj koronarnyjj sindrom // Medicinskijj vestnik Severnogo Kavkaza. 2007. № 3. S. 19-23.